
NIST's Sensor Technique Provides Faster Testing for Antibiotic Susceptibility
A new antibiotic susceptibility testing device developed by scientists at the National Institute of Standards and Technology could offer doctors a faster way to prescribe the right antibiotic.
With researchers around the world on the hunt for new ways to fight antibiotic-resistant bacteria, scientists from the National Institute of Standards and Technology (NIST) have developed a device that can detect if an antibiotic is effective against a specific pathogen.
Last year a
To this end, researchers have been developing tools to differentiate between
The new prototype sensor works by using a quartz crystal resonator coated with bacterial cells to detect changes in vibrations when particles on the surface change. The highly sensitive crystals allow researchers to measure changes in cell-generated frequency noise—which correlates with the density of living bacterial cells—created by the bacteria activity in response to exposure to antibiotics.
For example, when testing the device on Escherichia coli bacteria exposed to the antibiotics ampicillin and polymyxin B, the researchers observed a sharp drop in frequency noise within 7 and 15 minutes, respectively, of exposure to the antibiotics, reflecting the speed at which antibiotics begin to work.
Contagion® spoke about the study with senior author and NIST physicist Ward L. Johnson, PhD, who explained that the research was aimed at solving physicians’ needs to quickly choose the right antibiotic when writing prescriptions for patients, properly treat patients, and practice antibiotic stewardship. “However, it is often impossible for physicians to achieve the goal of responsible antibiotic use while protecting the health of a patient, because of a lack of timely information on the efficacy of antibiotics in treating a specific infection,” said Dr. Ward. “This untenable situation is driving efforts to develop rapid methods for antimicrobial susceptibility testing, such as our work.”
Although much additional research is needed on the new sensor before it can be developed for use in a clinical setting, Dr. Johnson sees a potential for the use of his tool alongside others, such as a rapid diagnostic device, to help doctors quickly diagnose and treat patients. “Advanced DNA/RNA-based technologies can identify microbes quickly but cannot directly determine antibiotic efficacy and, therefore, are limited in their ability to determine effective antibiotics for bacterial strains with new resistance mechanisms,” explained Dr. Johnson. “We envision that these technologies could be employed in tandem with our sensing approach to identify newly resistant strains.”
The timing could not be more appropriate, as, in the United States alone, an estimated 2 million people become infected with
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.